Treatment of chronic hepatitis C: Comparative virologie response rates among the different interferons

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 232-236

  Lindsay, Karen L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alpha interf rons; Beta interferons; Consensus ifn; Interferon; Virologie response rates

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALANINE AMINOTRANSFERASE; ALPHAN1 INTERFERON; BETA INTERFERON; CONSENSUS INTERFERON; MACROGOL; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER HISTOLOGY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETREATMENT; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA;

EID: 0033454094     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Lindsay KL. Therapy of hepatitis C: Overview. Hepatology 1997: 26 (Suppl 1): 71S-77.
2. Zoon KC, Miller D, Bekisz J, zur Nedden D, Enterline JC, Nguyen NY et al. Purification and characterization of multiple components of human lymphoblastoid interferon-or. J Biol Chem 1992: 267: 15210-15216.
3. Farrell GC, Bacon BR, Goldin RD, and the Clinical Advisory Group for the Hepatitis C Comparative Study. Lymphoblastoid interferon alpha-nl improves the long-term response to a 6month course of treatment in chronic hepatitis C compared with recombinant interferon alpha-2b. Results of an international randomized controlled trial. Hepatology 1998: 27: 1121-1127.
4. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferonalpha species, consensus interferon. J Interferon Cytokine Res 1996: 16: 489-499.
5. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keefe EB et al. Treatment of chronic hepatitis C with consensus interferon. A multicenter, randomized, controlled trial. Hepatology 1997: 26: 747-754.
6. Heathcote EJL, Keefe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998: 27: 1136-1143.
7. Amgen (data on file) or Heathcote EJL (personal communication).
8. Xu Z-X, HoiTman J, Patel I, Joubert P. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylatedinterferon (PEG-IFN) and interferon a-2a (IFN a-2a) to healthy subjects. Hepatology 1998: 28: 702A.
9. Shiffman M, Pockros PJ, Reddy RK, Wright TL. A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon alpha-2a (PEG) vs. standard alpha-2a (IFN) for treatment of chronic hepatitis C (Abstract). Gastroenterology 1999 (in press).
10. Heathcote EJ, Fried MW, Bain MA, DePamphilis J, Modi M. The pharmacokinetics of pegylated-40K interferon alpha-2a (PED-IFN) in chronic hepatitis C (CHC) patients with cirrhosis. Gastroenterology 1999 (in press).
11. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-/? therapy. Hepatology 1997: 25: 750-753.
12. Habersetzer F, Marcellin P, Boyer N, Zoulim F, Chossegros P, Erlinger S et al. Recombinant interferon beta for the treatment of chronic hepatitis C. Hepatology 1995; 22: 119A.
13. Castro A, Suarez D, Inglada L, Carballo E, Dominguez A, Diago M et al. Multicenter randomized, controlled study of intramuscular administration of interferon-/? for the treatment of chronic hepatitis C. J Interferon Cytokine Research 1997: 17: 27-30.
14. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998: 339: 1485-1492.
15. Davis GD, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998: 339: 1493-1499.
16. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al. Randomised trial of interferon ct2b plus ribavirin for 48 weeks or for 24 weeks versus interferon or2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998: 352: 1426-1432.